| 1 |
33946220 | Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients. | 2021 Apr 30 |
1 |
| 2 |
30483760 | The oncometabolite d‑2‑hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway. | 2019 Feb |
2 |
| 3 |
30958073 | Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications. | 2019 Nov |
2 |
| 4 |
31361380 | Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants. | 2019 Oct |
2 |
| 5 |
27721426 | Isocitrate dehydrogenase mutations in myeloid malignancies. | 2017 Feb |
1 |
| 6 |
28401022 | The clinical significance of isocitrate dehydrogenase 2 in esophageal squamous cell carcinoma. | 2017 |
4 |
| 7 |
25956465 | Metabolic consequences of oncogenic IDH mutations. | 2015 Aug |
2 |
| 8 |
24374336 | Parallel evolution of IDH2 gene in cetaceans, primates and bats. | 2014 Jan 31 |
1 |
| 9 |
21289278 | Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. | 2011 Feb 22 |
2 |